RPhLink.com  The Pharmaceutical Care Network! FROM: VALLEY INDEPENDENT PHARMACY ALLIANCE PHARMACY NETWORK UPDATE   06-19-03 The meeting with Outlook Graphics, Jabas and RESTAT was delayed from last week to yesterday (Friday), The meeting went extremely well and we are scheduling a second meeting to siscuss implementation of the prescription benefit program. Outlook has over 1,000 plan members and is currently considering the co-pay differential option. This plan will increase the members co-pay by $5.00 if they use an out of network pharmacy in the Fox Valley. Attatched to this e-mail is a list of participating pharmacies (please check your information for accuracy). Network pharmacies will be expected to engage in utilization interventions and patient outcome practices. The success of the network is directly linked to the value we can provide in utilization and outcomes management. Otherwise, we are no different than any other program onthe street. If for any reason you so not wish to participate, please advise ASAP. I boiled the name of our group down to "Valley Independant Pharmacy Alliance". The first part "Valley" gives us some geographic scope without pigeon holing us strictly the Fox Valley. The second part "Independant Pharmacy" clearly identifies who we are. The third part "Alliance" I think communicates what we have accomplished by working together to serve patients and businesses in our communinity. I choose not to use network because it sounds to PBMish. Things are starting to role...more to come! Steve Steven C. Morton Morton Pharmacy 111 E. North Water St. Neenah, WI 54956 920-727-3854 920-727-3867 fax smorton@mortonpharmacy.com ©2000 RPhLink.com The Pharmaceutical Care Network! Previous page | Front page | In Pharmacy this week | RxNews1 | RxNews2 | Pharmacy Jobs | FROM: Coppertone®                           06/19/03 The Sun Safety Alliance and Coppertone® Suncare Products. As you know, no one is immune to the sun's harmful rays, responsible for more than 90 percent of all skin cancers. In fact, over one million new cases are reported each year in the United States, with the incidence of melenoma increasing faster than any other form of cancer. Since most people recieve nearly 80 percent of lifetime sun exposure by the age of 18, it's of vital importance to establish sun-safe practices among all of your customers. Sunscreens can be used on children as young as 6 months of age. The Sun Safety Alliance (SSA) is being established as a nonprofit coalition dedicated to the task of reducing the incidence of skin cancer in America by motivating people to adopt fand practice sun-safe behavior. The SSA's founding members are the NACDS (National Association of Chain Drug Stores) and Schering-Plkough HealthCare Products, maker of the Coppertone®  brand. The SSA will reach out to educators, parents and healthcare professionals. Introducing Coppertone® Spectrs 3™ - the next generation of sunscreen protection. We're pleased to enclose our latest innovation in sun protection. Coppertone® Spectra 3™ suncreens provide triple protection against harmful UV rays. The broadest spectrum triple protection available-deflects, scatters and absorbs UVA/UVB rays Contain zinc oxide, plus vitamins A, C and E Fragrance-free Waterproof and easy to rub in Pediatrition-tested. Coppertone® Spectra 3™ suncreens are available for adult use in SPFs 30 and 50, and for infants 6 months and older and chilfren in SPF 50. Try it yourself. Recommend it to your patients. The enclosed sample of Coppertone® Spectra 3™ is for you to try, so that you can recommend it to your patients with confidence. Sincerely, Fred Duchin Vice President, Suncare Marketing P.S. For additional information about the Sun Safety Alliance, visit the professional section of their Website at www.sunsafetyalliance.org. For additional information about  Coppertone® Spectra 3™ sunscreens, visit www.coppertone.com.                                                                          FROM: RANBAXY BRAND PRODUCTS DIVISION  06/19/03 600 College Road East, Suite 2100 Priceton, NJ 08540 (609) 720-9200 Ranbaxy Pharmaceuticals Brand Products Division and Cumberland Pharmaceuticals is pleased to announce the re-launch of Procto-Kit™, indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Procto-Kit™ is available in hydrocortisone concentrations of 2.5% and 1%. Procto-Kit™ is the only topical hydrocortisone prescription product available in a kit. Each kit contains a 1 oz. tube of hydrocortisone cream, 12 finger cots and 6 applicator tips. Procto-Kit™ 2.5% and 1% will be promoted on a nationwide basis by Cumberland Pharmaceuticals, and supported by national marketing efforts on part of Ranbaxy Pharmaceuticals Brand Products Division. The dedicated sales force of over 50 representatives will be calling on gastroenterologists and colo-rectal surgeons throughout the United States. These sales representatives will also be visiting your pharmacies regularly to answer any questions regarding Procto-Kit™. Procto-Kit™ is now available through your wholesaler and distributors. If your supplier does not stock Procto-Kit™, please call us at 1-888-RANBAXY (1-888-726-2299.  Now, through this executive one time offer get $15.00 off the purchase of 3 kits. Offer Valid on purchase of Procto-Kit™ 2.5% only. Ranbaxy Pharmaceuticals Brand Products Division and Cumberland Pharmaceuticals would like to thank you in advance for your support. We are committed to providing high quality products and service to you, at an affordable price. Best Regards, Kevin M. Kaul Executive Director, Brand Marketing Ranbaxy Pharmaceuticals Brand Products Division   ©2000 RPhLink.com The Pharmaceutical Care Network! Front page | In Pharmacy this week | RxNews1 | RxNews2 | Pharmacy Jobs |

FROM: ELI LILLY AND COMPANY www.lilly.com__ ____________________________________________________________________                Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 U.S.A __________________________________________________________________________________ Phone 317 276 2000_________________________________________________________________ May 16, 2003 Attn: Lilly Buyer RE:ZYPREXA Zydis (olanzapine) Orally Disintegrateing Tablets-Updated Stocking Information We wish to inform you that on June 6, 2003 Lilly will begin supporting ZYPREXA Zydis, the orally disintegrating form of ZYPREXA (olanzapine), with an extensive marketing campaign to community-based psychiatrists and community mental health centers. Until now, ZYPREXA Zydis has primarily been used in institutional and long-term care facilities. The additional marketing efforts to community-based healthcare professionals will be in conjunction with current marketing activities in these inpatient care settings. ZYPREXA Zydis is available in 5 mg, 10 mg, 15 mg, and 20 mg and is indicated for the treatment of schizophrenia, for maintenance of treatment response in schizophrenia, and for acute bipolar mania. ZYPREXA Zydis offers an alternative dosing form for patients who may be unable or reluctant to swallow regular tablets. We anticipate an increase in your current demand for all strengths of ZYPREXA Zydis. Initial Stocking Orders: Stocking incentives may be offered through your wholesaler. Please contact your wholesaler as soon as possible to discuss this opportunity. Sales Forecast: To assist you with your initial stocking quantities, Lilly anticipates that one ZYPREXA Zydis 10 mg 30-count Dose Pack should be stocked in pharmacies purchasing high volumes of ZYPREXA 10 mg tablets. Additionally, Lilly anticipates increased utilization of all four ZYPREXA Zydis strengths. Important Safety Information for ZYPREXA: In short-term schizophrenia and bipolar mania trials, the most common treatment-emergent adverse event associated with ZYPREXA was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite, and tremor. A small number of patients experienced asymptomatic elevations of hepatic tranaminase; none of these patients experienced jaundice. Prescribing should be consistent with the need to minimize the risk of tardive dyskinsia, seizures, and orthostatic hypotension. Phenylketonurics should be advised that ZYPREXA Zydis contains phenylalnine. For Prescribing information on ZYPREXA Zydis, please refer to www.ZYPREXA.com or call 1-800-545-5979. Very truly yours, Eli Lilly and Company   Retail Pharmacy Fact Sheet SUPPLIED BY:        Eli Lilly and Company MARKETED BY:       Eli Lilly and Company PRODUCT NAME:    ZYPREXA® Zydis® (Olanzaprine) Orally Disintegrating Tablets Sales Package Size Product Codes  NWP AWP ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4453-85 UPC: 3-0002-4453-85-2 Lilly: TA4453 $187.91 $225.49 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4454-85 UPC: 3-0002-4454-85-2 Lilly: TA4454 $270.35 $324.42 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4455-85 UPC: 3-0002-4455-85-2 Lilly: TA4455 $390.82 $468.98 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4456-85 UPC: 3-0002-4456-85-2 Lilly: TA4456 $510.60 $612.72 **Stocking incentives may be offered through your wholesaler. Please contact your wholesaler as soon as possible to discuss this opportunity. PRODUCT QUANTITY CASE DIMENSIONS CASE WEIGHT All Presentations of ZYPREXA Zydis 30-count Dose Packs 15 16.5 in x 9.8 in x 7.4 in 3.5 lb DATED ITEM:                           YES PRESCRIPTION LEGEND:           YES TEMPERATURE REQUIREMENTS: 68oF-77oF GUARANTEED SALE:                  12 months' possession required DISTRIBUTION:                         To Eli Lilly and Company Wholesalers RETURNED GOODS:                   See Eli Lilly and Company Return Goods Policy IMPORTANT:                              Eli Lilly and Company uses DDD (Drug Distribution Data) to aid in                                                 monitoring the success of our marketing efforts. Your timely and                                                 accurate reporting of this data for ZYPREXA Zydis will be appreciated.